82278-73-7

Basic information

• Product Name: (S)-N-Boc-3-Bromophenylalanine
• Synonyms: BOC-L-3-BROMOPHE;BOC-L-3-BROMOPHENYLALANINE;BOC-3-BROMO-L-PHENYLALANINE;BOC-S-PHE(3-BR)-OH;BOC-PHE(3-BR)-OH;(S)-3-(3-BROMO-PHENYL)-2-TERT-BUTOXYCARBONYLAMINO-PROPIONIC ACID;(S)-N-BOC-3-BROMOPHENYLALANINE;(S)-N-ALPHA-T-BUTYLOXYCARBONYL-3-BROMO-PHENYLALANINE
• CAS NO: 82278-73-7
• Molecular Formula: C₁₄H₁₈BrNO₄
• Molecular Weight: 344.2
• EINECS: 1592732-453-0
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids
• Mol File: 82278-73-7.mol

Chemical Properties

• Melting Point: 106.1°C
• Boiling Point: 475.3 °C at 760 mmHg
• Flash Point: 241.2 °C
• Appearance: off-white powder
• Density: 1.5311 (rough estimate)
• Vapor Pressure: 7.71E-10mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: Store at 0°C
• PKA: 3.81±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (S)-N-Boc-3-Bromophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Boc-3-Bromophenylalanine(82278-73-7)
• EPA Substance Registry System: (S)-N-Boc-3-Bromophenylalanine(82278-73-7)

Safety Data

• Safety Statements: S24/25:Avoid contact with skin and eyes.
• HazardClass: IRRITANT
• Hazardous Substances Data: 82278-73-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-Boc-3-Bromophenylalanine is used as a pharmaceutical intermediate for the synthesis of various bioactive compounds and drug candidates. Its unique structure allows for the development of novel therapeutic agents with potential applications in treating a wide range of diseases and medical conditions.
Used in Organic Synthesis:
(S)-N-Boc-3-Bromophenylalanine is used as a key building block in organic synthesis, enabling the creation of complex organic molecules with specific biological activities. Its bromo substituent and Boc protecting group facilitate various synthetic transformations, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
(S)-N-Boc-3-Bromophenylalanine is utilized in research and development settings to explore its potential as a precursor for the synthesis of innovative compounds with unique properties. Its chiral nature and functional groups make it an attractive target for studying the structure-activity relationships of various bioactive molecules and for developing new synthetic methodologies.

InChI:InChI=1/C14H18BrNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-5-4-6-10(15)7-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 880347-42-2 2-amino-3-(3-bromo-phenyl)-N-((2R)-hydroxy-(1R)-methyl-2-phenyl-ethyl)-N-methyl-propionamide 
• 14473-91-7 3-bromocinnamic acid 

Downstream Products

• 468740-94-5 tert-butyl[(1S)-1-(3-bromobenzyl)-2-hydroxyethyl]carbamate 
• 546115-43-9 methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 1159502-91-6 ethyl (2S)-3-(3-bromophenyl)-2-(tertbutoxycarbonylamino)propanoate 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 
• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-76-9 (S)-2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propanol 
• 1430058-03-9 (2S)-2-amino-3-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]propan-1-ol 
• 1430057-96-7 (2S)-2-amino-3-(3-cyanophenyl)propan-1-ol 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

Intensified biocatalytic production of enantiomerically pure halophenylalanines from acrylic acids using ammonium carbamate as the ammonia source

An intensified, industrially-relevant strategy for the production of enantiopure halophenylalanines has been developed using the novel combination of a cyanobacterial phenylalanine ammonia lyase (PAL) and ammonium carbamate reaction buffer. The process boasts STYs up to >200 g L-1 d-1, ees ≥ 98% and simplified catalyst/reaction buffer preparation and work up.

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.

MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE

The invention provides compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and metho

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.